NASDAQ:ALRN - Aileron Therapeutics Stock Price, Forecast & News

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics Inc (NASDAQ:ALRN) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.28) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.05. View Aileron Therapeutics' Earnings History.

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aileron Therapeutics.

3 brokerages have issued 1-year price objectives for Aileron Therapeutics' shares. Their forecasts range from $5.00 to $6.00. On average, they expect Aileron Therapeutics' stock price to reach $5.50 in the next year. This suggests a possible upside of 587.5% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

News coverage about ALRN stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aileron Therapeutics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Aileron Therapeutics.

Some companies that are related to Aileron Therapeutics include Elite Pharmaceuticals (ELTP), Catalyst Biosciences (CBIO), VERONA PHARMA P/S (VRNA), ASLAN PHARMACEU/ADR (ASLN), ESSA Pharma (EPIX), IMMUTEP LTD/S (IMMP), Trevena (TRVN), Catabasis Pharmaceuticals (CATB), CTI BioPharma (CTIC), Neos Therapeutics (NEOS), Eyenovia (EYEN), Oncolytics Biotech (ONCY), Cumberland Pharmaceuticals (CPIX), Aclaris Therapeutics (ACRS) and NewLink Genetics (NLNK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Lexicon Pharmaceuticals (LXRX), Iovance Biotherapeutics (IOVA), Corbus Pharmaceuticals (CRBP), Aurora Cannabis (ACB), Abeona Therapeutics (ABEO), Cronos Group (CRON), Aclaris Therapeutics (ACRS), Amarin (AMRN) and Fate Therapeutics (FATE).

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALRN stock can currently be purchased for approximately $0.80.

Aileron Therapeutics has a market capitalization of $22.25 million. The company earns $-31,550,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

The official website for Aileron Therapeutics is http://www.aileronrx.com/.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]